Is it over for Ozempic? Study reveals weight regain in some patients after stopping Ozempic and Wegovy
Losing weight can be a challenging journey for many individuals, especially those struggling with diabetes. However, the introduction of medications like Ozempic and Wegovy brought hope to those looking to shed pounds while managing their condition. These drugs, which gained immense popularity for their dual benefits of treating diabetes and aiding weight loss, seemed like a game-changer. But a recent study has revealed a concerning trend – about one in five patients are unable to maintain their weight loss after discontinuing the use of these medications.
The study, conducted by Epic Research, examined the experiences of 20,274 patients who had used drugs like Ozempic and Wegovy. The participants were observed for a year after they stopped taking the medications. The findings were alarming – 17.7% of the patients regained all the weight they had lost, and in some cases, even gained more weight than before.
One of the patients interviewed, Artemis Bayandor, shared her struggle after stopping Wegovy. She had initially lost 15 pounds while on the medication but experienced a significant weight gain after discontinuing its use. “The weight started coming on like never before,” she said. Bayandor also mentioned having an aggressive appetite, something the medication had helped suppress. “I was insatiable. And I’ve never been that way. I was so hungry. It was crazy the way it felt,” she added.
Despite these disheartening accounts, the study did bring some positive news. Two-thirds of the patients who stopped using either semaglutide (Ozempic) or liraglutide (Saxenda) were able to maintain their weight loss progress. This suggests that for a majority of users, the benefits of these medications extend beyond their active usage period.
Furthermore, 56.2% of patients managed to either maintain their weight at the time of quitting or continued to lose weight. This indicates that the medications had a lasting impact on their metabolism and eating habits, even after discontinuation.
It is important to note that the study also revealed that a significant number of individuals who had lost at least 5 pounds on liraglutide were able to maintain their weight or continue shedding pounds after stopping its use. This finding provides hope for those considering these medications as a weight loss solution.
In addition to the weight regain concerns, recent unrelated research has suggested that Ozempic might have an additional benefit for certain diabetes patients. It could potentially double as a liver cancer preventative. This discovery adds another layer of complexity to the overall assessment of these medications.
While the study’s findings raise questions about the long-term effectiveness of Ozempic and Wegovy in maintaining weight loss, it is crucial to remember that individual experiences may vary. Weight management is a multifaceted journey, and medications alone may not guarantee sustained results. Lifestyle changes, including diet and exercise, remain essential components of any weight loss plan.
As researchers continue to explore the intricacies of these medications, it is important for patients to consult with their healthcare providers before making any decisions regarding their treatment. The study’s findings serve as a reminder that personalized approaches are necessary when it comes to managing weight and diabetes effectively.
In conclusion, the study reveals that while some patients may experience weight regain after stopping Ozempic and Wegovy, a majority of users are still able to maintain their weight loss progress. These medications continue to offer hope for individuals struggling with diabetes and obesity. However, it is crucial to approach their usage as part of a comprehensive treatment plan that includes lifestyle modifications. As the medical community delves deeper into understanding the long-term effects of these drugs, patients must work closely with their healthcare providers to find the best approach for their individual needs.
